Truepill, a San Mateo, Calif.-based company building patient experiences through its API-connected healthcare infrastructure, closed a $75m Series C funding.
Backers included Oak HC/FT (lead), and existing investors Optum Ventures, TI Platform Management, Sound Ventures and YCombinator.
The funds will be used to launch an at-home lab testing network – a new service that will further expand the company’s ecosystem of direct-to-patient capabilities, which includes Truepill Health telehealth network, pharmacy fulfillment, a custom-built EMR, and more.
Led by Umar Afridi, CEO and Co-founder, and Sid Viswanathan, Co-founder and President, Truepill leverages APIs to provide customized B2B solutions for healthcare companies of all sizes, stages and specialties, including many direct-to-consumer health brands. As its customers expand product offerings and enter new markets, Truepill continues enhancing its platform.
The company plans to launch its newest service, at-home lab testing, by end of year. By combining at-home testing with telehealth and prescription delivery, the company will enable the diagnosis and management of the largest chronic disease states, including diabetes, heart disease, chronic kidney disease, and more.
Its owned and operated pharmacies are located in Hayward, CA, Brooklyn, NY, Redmond, WA, Alhambra, CA, Austin, TX and Manchester, England. Truepill accreditations include URAC accredited mail order pharmacy, URAC accredited specialty pharmacy, NABP, Digital Pharmacy Accreditation and LegitScript.